Tim van Tienhoven

Excited to share our preprint 🩸🦴

"Targeting mitochondria mitigates chemotherapy-induced bone marrow dysfunction"

Proud of our team #MansellLab @elsydutchy.bsky.social @johannalepland.bsky.social and all co-authors 🎉

#Hemesky #Hematology #StemCell #MitochondrialBiology #Metabolism

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia Enhancer translocations, due to 3q26 rearrangements, drive out-of-context MECOM expression in an aggressive subtype of acute myeloid leukemia (AML). Direct depletion of MECOM using an endogenous auxin...

Excited to share our preprint on #HemeSky: "MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia"! @delwelruud.bsky.social and co-authors! www.biorxiv.org/content/10.1... [1/15]

✨Extremely grateful for this bunch this year! The #MansellLab grew, got some more funding, worked hard and played hard!✨ Excited for 2025, in which we hope to publish our first work 📝get more techniques under our belt 🧫 and continue having fun doing what we’re doing! #HemeSky

Our Travel Grant winners' experience at Cancer Metabolism 2024 - The Cancer Researcher Hear from our Travel Grant winners at the EACR conference 'Cancer Metabolism' 2024

"I found myself in awe of the confidence, presentation style and even the design ideas of the fellow presenters"

Read about the experiences of recent Travel Grant winners at Cancer Metabolism 2024: magazine.eacr.org/our-travel-g...

Could you please add me to this mito pack.

Would love to be added to this pack!

Could you please add me to this pack